Skip to content

Mixed Phenotype Acute Leukemia With T 9 22 Q34 1 Q11 2 C2826037

Published: July 22, 2026Updated: August 20, 2026

A rare, aggressive blood cancer with features of both lymphoid and myeloid leukemia. Marked by the Philadelphia chromosome. Treated with intensive chemotherapy and possibly stem cell transplant.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C96.9
ICD-11
2A00.0
Body system
hematologic
Severity
critical
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Generalized symptoms

Symptoms may be severe and require urgent medical attention.

Seek immediate emergency care if symptoms are severe or worsening rapidly.

!

Severe headache

Fatigue

(hematologic)

Mucosal bleeding

(hematologic)

Bone pain

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Multi-agent induction chemotherapy

Intensive multi-drug chemotherapy regimen combining corticosteroids, vincristine, and asparaginase with tyrosine kinase inhibitor therapy targeting the BCR-ABL1 fusion protein characteristic of t(9;22).

medication
2

Percutaneous intervention with follow-up

Requires immediate emergency medical intervention. Do not delay treatment.

procedure
3

Allogeneic stem cell transplantation

Hematopoietic stem cell transplant from matched related or unrelated donor following complete remission achieved through chemotherapy. Represents potentially curative option for eligible patients.

procedure

Additional treatment options

Tyrosine kinase inhibitor maintenance

Continuous therapy with BCR-ABL1 inhibitors such as imatinib, dasatinib, or ponatinib to maintain molecular remission and prevent relapse in Philadelphia chromosome-positive leukemia.

medication

Consolidation chemotherapy

Additional intensive chemotherapy cycles following induction to eliminate residual leukemia cells and deepen remission before transplant consideration or continued maintenance.

medication

Minimal residual disease monitoring

Serial molecular and flow cytometry monitoring of minimal residual disease through quantitative PCR for BCR-ABL1 transcripts and immunophenotyping to detect early relapse.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Mixed Phenotype Acute Leukemia With T 9 22 Q34 1 Q11 2 C2826037?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Placeholder A, Placeholder B, Placeholder C. Clinical practice guidelines for mixed phenotype acute leukemia with t(9;22)(q34;q11.2). Example J Guidelines. 2023.

guideline2023
2

Example D, Example E. Molecular characterization of MPAL with BCR-ABL1 fusion. Sample Hematol Rev. 2022.

review2022
3

Placeholder F, Placeholder G, Placeholder H. Immunophenotypic features and outcomes in MPAL t(9;22) cases: A retrospective analysis. Demo Leuk Res. 2021.

other2021
4

Placeholder I, Placeholder J. NCCN Guidelines Summary: Acute leukemia variants including mixed phenotype acute leukemia. Sample Oncol Princ. 2023.

guideline2023

Medication Comparisons

Compare medications used to treat Mixed Phenotype Acute Leukemia With T 9 22 Q34 1 Q11 2 C2826037. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy